← All companies

ACRS

Aclaris Therapeutics, Inc.

ACRS Nasdaq Pharmaceutical Preparations EDGAR ↗

$5.53

+0.33 +6.35%

Key statistics

from XBRL data in SEC filings

Market cap

$772M

Revenue (TTM)

$8.37M

Net income (TTM)

-$69.7M

EPS (TTM)

$-0.56

P/E ratio

—

Dividend yield

—

Free cash flow

-$47.2M

Cash

$28.7M

Total assets

$199M

Gross margin

38.7%

52-week range

$1.52 – $5.88

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Shareholder vote results Jun 4, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 8-K Regulation FD disclosure; Other events Apr 28, 2026 8-K Regulation FD disclosure Mar 11, 2026 8-K Regulation FD disclosure Mar 10, 2026 10-K Fiscal year ended 2025-12-31 Feb 26, 2026 8-K Results of operations (earnings release) Feb 26, 2026 8-K Regulation FD disclosure Jan 12, 2026 8-K Regulation FD disclosure; Other events Jan 6, 2026 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Regulation FD disclosure Oct 14, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Regulation FD disclosure; Other events Jul 29, 2025 8-K Regulation FD disclosure Jun 30, 2025 8-K Director or officer change; Amended charter or bylaws; Shareholder vote results Jun 5, 2025 10-Q Quarter ended 2025-03-31 May 8, 2025 8-K Results of operations (earnings release); Regulation FD disclosure May 8, 2025 10-K Fiscal year ended 2024-12-31 Feb 27, 2025 8-K Results of operations (earnings release) Feb 27, 2025 8-K Regulation FD disclosure Jan 13, 2025 8-K Entered a material agreement; Unregistered sale of equity; Director or officer change; Regulation FD disclosure; Other events Nov 18, 2024 10-Q Quarter ended 2024-09-30 Nov 6, 2024 8-K Results of operations (earnings release) Nov 6, 2024 10-Q Quarter ended 2024-06-30 Aug 7, 2024 8-K Results of operations (earnings release) Aug 7, 2024 8-K Entered a material agreement; Regulation FD disclosure Jul 16, 2024 8-K Shareholder vote results Jun 7, 2024 10-Q Quarter ended 2024-03-31 May 7, 2024 8-K Results of operations (earnings release); Regulation FD disclosure May 7, 2024 8-K Director or officer change Mar 19, 2024 10-K Fiscal year ended 2023-12-31 Feb 27, 2024 8-K Results of operations (earnings release) Feb 27, 2024 8-K/A Director or officer change Feb 5, 2024 8-K Director or officer change Feb 5, 2024 8-K Results of operations (earnings release); Director or officer change Jan 19, 2024 8-K Exit or disposal costs; Regulation FD disclosure Dec 19, 2023 8-K Regulation FD disclosure; Other events Nov 13, 2023